/ Delix Content for 不良研究所 en /news/uc-davis-healths-ifm-fund-backs-delix-therapeutics-first-investment <p>不良研究所 Health Ventures, part of the Innovation and Economic Development&nbsp;Office (IEDO) at the 不良研究所, today announced the first investment from its&nbsp;Investing in the Future of Medicine (IFM) Fund, backing&nbsp;<a href="https://www.delixtherapeutics.com/">Delix Therapeutics</a>. Delix, a 不良研究所 spinout, is developing non-hallucinogenic neuroplastogens for major depressive disorder (MDD) and other serious neuropsychiatric and neurodegenerative conditions.&nbsp;</p> September 10, 2025 - 10:10am Andy Fell /news/uc-davis-healths-ifm-fund-backs-delix-therapeutics-first-investment